|
Waldenstrom Macroglobulinemia
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<b>Purpose:</b> Everolimus inhibits mTOR, a component of PI3K/AKT prosurvival signaling triggered by MYD88 and CXCR4-activating mutations in Waldenstrom macroglobulinemia.<b>Experimental design:</b> We evaluated everolimus in a prospective, multicenter study of 33 symptomatic, previously untreated Waldenstrom macroglobulinemia patients.
|
27836860 |
2017 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<i>Results</i>: MYD88 L265P mutations were detected in 22 of 29 samples from 14 patients with diffuse large B-cell lymphomas and one patient with lymphoplasmacytoid lymphoma.
|
31603365 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Waldenström macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M. Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis.
|
28366781 |
2017 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MYD88 L265P was absent in paired normal tissue samples from patients with Waldenström's macroglobulinemia or non-IgM LPL and in B cells from healthy donors and was absent or rarely expressed in samples from patients with multiple myeloma, marginal-zone lymphoma, or IgM monoclonal gammopathy of unknown significance.
|
22931316 |
2012 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MYD88 (L265P) was detected in 58/58 (100%) patients with WM, 36/77 (47%) with IgM-MGUS, 5/84 (6%) with SMZL, and 3/52 (4%) with B-CLPD.
|
23355535 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MYD88 L265P mutation has been reported in ∼90% of Waldenström's Macroglobulinemia (WM) patients and immunoglobulin M (IgM) monoclonal gammopathies of uncertain significance (MGUS), as well as in some cases of lymphoma and chronic lymphocytic leukemia.
|
24992174 |
2015 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MYD88(L265P) and CXCR4(WHIM) mutations are highly prevalent in Waldenström's macroglobulinemia.
|
25853747 |
2015 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MYD88 and CXCR4 mutations affect WM disease presentation and treatment outcome.
|
28294689 |
2017 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MYD88 L265P mutation in cutaneous involvement by Waldenström macroglobulinemia.
|
28370087 |
2017 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
MyD88-loaded EVs were detected in the bone marrow aspirates of WM patients thus establishing the physiological role of EVs for MyD88<sup>L265P</sup> transmission and shaping of the proinflammatory microenvironment.
|
29358175 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MYD88 mutation has been reported in various lymphomas, specifically in lymphoplasmacytic lymphoma.
|
31576141 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.
|
24224040 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A new era for Waldenstrom macroglobulinemia: MYD88 L265P.
|
23723443 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
|
31276195 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Abnormalities that affect myeloid differentiation primary response 88 (MYD88)--interleukin-1 receptor-associated kinase 4 (IRAK4) and nuclear factor kappa B (NF-κB) signaling pathways were found in a significant proportion of WM cases, which suggest their relevance in the pathogenesis of the disease and opening new avenues that may be a guide to design novel therapeutic approaches.
|
23477936 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although not entirely specific, MYD88 L265P is a useful adjunct for bone marrow diagnosis in separating LPL from other small B-cell lymphomas and plasma cell myeloma.
|
23955458 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although the absence of the MyD88 L265P somatic mutation in our SS cohort does not exclude a common germline susceptibility gene in SS, it might suggest a distinct operating pathogenetic mechanism in SS-related lymphoma compared with WM and other hematological malignancies.
|
24153350 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among WM and IgM-MGUS, MYD88 L265P mutation was associated with some differences in clinical and biological characteristics, although usually minor; wild-type MYD88 cases had smaller M-component (1.77 vs 2.72 g/dl, P=0.022), more lymphocytosis (24 vs 5%, P=0.006), higher lactate dehydrogenase level (371 vs 265 UI/L, P=0.002), atypical immunophenotype (CD23-CD27+ +FMC7+ +), less Immunoglobulin Heavy Chain Variable gene (IGHV) somatic hypermutation (57 vs 97%, P=0.012) and less IGHV3-23 gene selection (9 vs 27%, P=0.014).
|
23446312 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
An oncogenic gain-of-function mutation (L265P) in the human MYD88 gene has been found to be present in most cases of WM/LPL, yet is absent in most other cases of B-cell chronic lymphoproliferative disorders (LPD), including SMZL.
|
24842316 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Beyond the discovery of the myeloid differentiation primary response gene 88 (MYD88) L265P mutation, which will help greatly in the differential characterization of WM from other B-cell low-grade lymphomas, several other mechanisms of gene deregulation were identified and mapped that recurrently pointed out nuclear factor-kappa B (NF-κB), breakpoint cluster region (BCR), and Toll-like receptor (TLR) signaling pathways as potential targets for a better understanding of the physiopathology of WM and for future drug development.
|
23473949 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.
|
31221512 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Clinical features of WM such as hyperviscosity were uncommon in this group and did not correlate with MYD88 status.
|
27329639 |
2016 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
|
27890075 |
2016 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcome.
|
25197661 |
2014 |